Neil Dahiya

BioNxt Solutions Unveils Sublingual Thin-Film ODF for Semaglutide Development

BioNxt Solutions Inc., specializing in cutting-edge drug delivery technologies, has announced its latest project: a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, labeled internally as BNT24005. This groundbreaking product aims to enhance the current administration techniques developed by Novo […]

BioNxt Solutions Unveils Sublingual Thin-Film ODF for Semaglutide Development Read More »

AAVB-081 Receives Rare Disease Status from US FDA for Usher Syndrome Type 1B Retinitis Pigmentosa Treatment

AAVantgarde Bio, a clinical-stage biotech firm headquartered in Italy, revealed that the US Food and Drug Administration (FDA) has awarded Orphan Drug Status to its leading initiative, AAVB-081, aimed at treating Usher Syndrome Type 1B (USH1B) retinitis pigmentosa. “Individuals with

AAVB-081 Receives Rare Disease Status from US FDA for Usher Syndrome Type 1B Retinitis Pigmentosa Treatment Read More »

Endo Launches FDA-Approved Ready-to-Use Adrenalin Premixed IV Bag in the USA

Endo, Inc., a versatile company specializing in pharmaceuticals, has unveiled its new Adrenalin premixed bag, marking the first ever epinephrine in 0.9% sodium chloride injection that is FDA-approved and manufacturer-prepared for intravenous (IV) use. “This groundbreaking ready-to-use bag of epinephrine

Endo Launches FDA-Approved Ready-to-Use Adrenalin Premixed IV Bag in the USA Read More »

PTC and Novartis Form Global Partnership for Huntington’s Disease Treatment PTC518

PTC Therapeutics, Inc., a globally recognized biopharmaceutical firm, has entered into a worldwide license and collaboration agreement with Novartis Pharmaceuticals Corporation, a division of Novartis AG. This partnership centers on PTC518, a program designed to innovate treatment for Huntington’s disease,

PTC and Novartis Form Global Partnership for Huntington’s Disease Treatment PTC518 Read More »

Novocure Unveils Encouraging Trial Outcomes for TTFields Treatment in Pancreatic Cancer

Novocure recently disclosed favorable initial results from its Phase 3 investigation of Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The PANOVA-3 study revealed a notable enhancement in overall survival for patients with non-resectable, locally advanced pancreatic adenocarcinoma treated with

Novocure Unveils Encouraging Trial Outcomes for TTFields Treatment in Pancreatic Cancer Read More »

Exactech Showcases Initial Surgeries with Ankle Replacement Navigation System

Exactech recently confirmed the inaugural surgical procedures using its innovative Exactech GPS Ankle system for comprehensive ankle replacement. Dr. Edward Haupt, affiliated with Mayo Florida in Jacksonville, had the honor of performing the first-ever surgery with this technology. Haupt was

Exactech Showcases Initial Surgeries with Ankle Replacement Navigation System Read More »

Nervonik Achieves Milestone with Initial Human Trial of Nerve Stimulation Technology for Chronic Pain

Nervonik has successfully concluded its inaugural human clinical trial involving their peripheral nerve stimulation (PNS) device. Based in Los Angeles, the innovative startup has engineered a unique device aimed at improving therapeutic outcomes for chronic pain management. This technology utilizes

Nervonik Achieves Milestone with Initial Human Trial of Nerve Stimulation Technology for Chronic Pain Read More »